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Abstract Overexpression of the epidermal growth factor
receptor (EGFR) occurs in many tumors and in breast cancer
correlates with poor prognosis for treatment. Here, we report
that interferon regulatory factor-1 (IRF-1) induces EGFR
promoter activity up to 200-fold compared to 3^10-fold induction
by other regulators. The region of the promoter that is required
for this induction was defined using deletion mutants. In addition,
we found that IRF-1 and tricostatin A, a deacetylase inhibitor,
have a synergistic effect on EGFR promoter activity. This
indicates that the increase in EGFR promoter activity by IRF-1
may also involve changes in chromatin structure. These results
identify IRF-1 as a major regulator of EGFR gene expression.
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1. Introduction
Epidermal growth factor receptor (EGFR) gene expression
has to be precisely regulated to insure proper cell growth.
Overexpression of EGFR in breast cancer correlates with fail-
ure on endocrine therapy [1,2]. The EGFR is considered a
marker for cell transformation [3,4], and therefore it has
been an attractive target for clinical intervention.
The EGFR promoter contains binding sites for transcrip-
tion factors, such as SP1, AP2, p53, WT1, and GCF [5^9].
The level of induction or repression by most reported tran-
scription factors ranges between 3- and 10-fold. Many di¡er-
ent types of agents have been reported to regulate EGFR gene
expression including interferons (IFNs) [10,11]. However, the
mechanism by which interferons upregulate EGFR gene ex-
pression is unknown. IFNs are known to induce the expres-
sion of interferon regulatory factor-1 (IRF-1). IRF-1 is a
member of a family of regulatory factors that are highly ho-
mologous in their DNA binding domains and bind to the
interferon stimulated response element (ISRE) sequences
[12^14]. IRF-1 is an important transcription factor that mod-
ulates the expression of many of the IFN-inducible genes.
The focus of this study is to determine whether IRF-1 has a
major role in modulating EGFR gene expression. Such under-
standing will help in the search for new approaches to control
the expression of EGFR in malignant tumors and in breast
cancer in particular.
2. Materials and methods
2.1. Materials
The human breast cancer cell line MCF-7 was purchased from
ATCC. U3A cells were a gift from G. Stark. All cells were propagated
in Dulbecco’s modi¢ed Eagle’s medium (Life Technologies) in the
presence of 10% fetal calf serum. Luciferase constructs of the
EGFR promoter, pERLUC-1, pERLUC-4, pERLUC-5, pERLUC-6
and pERLUC-9, were prepared by ligating HindIII promoter frag-
ments from pERCAT constructs [5] into pGL-basic (Promega). The
IRF-1 expression vector (pAct-1) was a gift from T. Taniguchi. The
pBS based plasmid for in vitro transcription/translation was a gift
from K. Ozato.
2.2. Luciferase assays
U3A cells grown in triplicate in 35 mm diameter plates were trans-
fected with the appropriate expression vector by lipofectamine (Life
Technologies). The EGFR promoter reporter plasmids (500 mg) were
cotransfected with the indicated amount of IRF-1 expression vector
and with the empty vector LK440. DNA concentration was kept
constant by addition of herring sperm DNA. Cells were harvested
24 h after transfection and cell extracts prepared according to the
protocol from Analytical Luminescence Laboratory. All luciferase
activities were normalized for protein concentration. All experiment
were performed in triplicate or more.
2.3. Electrophoretic mobility shift assays
Double-stranded DNA oligonucleotides were used for electro-
phoretic mobility shift assays (EMSAs). EGFRp-75: GCCGACAA-
ACACAGTTCGGAAATAAGGTTCTCGAAGTGAAAACGCTTC,
EGFRp-132: GTGTAACCGAAGTTTCATGGGTACCGACCAA-
CGTTATTTGTAA, and IRF-1-3n: AAGTGAAAGTGAAAGTGA-
AAGTGA (the IRF-1 binding site [14]). As a non-speci¢c competitor
(NS), a 42 bp oligonucleotide GCF2-3x was used.
IRF-1 was generated by coupled in vitro transcription/translation
using reticulocyte lysates (Promega). IRF-1 was incubated with dou-
ble-stranded end-labeled oligonucleotides in a bu¡er containing 1 Wg
of poly(dI-dC). The protein-DNA complexes were resolved by electro-
phoresis on a 5% polyacrylamide gel.
2.4. Western blotting
Whole cell extracts (30 Wg) were resolved on a 4^12% SDS-PAGE,
transferred onto PVDF membrane (Novex), followed by immunoblot-
ting using the ECL detection system as suggested by the manufacturer
(Amersham).
3. Results and discussion
To understand what factors modulate the induction of the
EGFR by IFNQ, we examined the response to one of the
major transcription factors induced by IFNs, IRF-1. Since
IRF-1 is known to be induced by STAT-1 [15], the human
¢broblast cell line U3A was chosen for this experiment be-
cause it lacks the expression of STAT-1 [16]. This enabled us
to eliminate possible e¡ects of endogenous STAT-1. To deter-
mine the e¡ect of this factor on EGFR promoter activity, we
FEBS 20537 20-7-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 7 7 4 - 1
*Corresponding author. Fax: (1) (301) 496-2212.
E-mail: aj2e@nih.gov
FEBS 20537FEBS Letters 431 (1998) 268^272
cotransfected the full-length EGFR promoter construct, pER-
LUC-1 (Fig. 1a) with increasing amounts of the IRF-1 ex-
pression vector. This resulted in a dose-dependent increase
of up to 200-fold in luciferase activity (Fig. 1b). Such high
levels of induction of EGFR promoter activity have not been
previously reported.
The dramatic increase of the EGFR promoter activity by
IRF-1 prompted us to examine whether IRF-1 could induce
the expression of the endogenous EGFR. We selected MCF-7
breast cancer cells to examine this because they have been
used as a model system to study the e¡ect of EGF on human
breast cancer cells and they express low levels of EGFR
[17,18]. MCF-7 cells were transfected with IRF-1 expression
vector and the expression of the EGFR was analyzed by
Western blotting. As shown in Fig. 1c, there is a 10-fold in-
crease in EGFR expression in cells transfected with IRF-1
expression vector. Our Western analysis of MCF-7 cells con-
¢rmed the induction of the EGFR expression by IFNQ (data
not shown), as had been previously reported [19,20]. This
experiment indicates that IRF-1 can induce endogenous
EGFR expression as well as the transfected EGFR promoter
activity.
To localize the region of the promoter that is required for
the increased activity by IRF-1, deletion mutants of the
EGFR promoter were constructed (Fig. 2a). As shown in
Fig. 2b, the induced activity of the EGFR promoter decreased
dramatically from pERLUC-1 to pERLUC-4, after deletion
of 198 nucleotides (Fig. 2b). These results indicated that the
region between 31109 and 3911 in the EGFR promoter is
required for maximal induction by IRF-1. To further analyze
the nature of the IRF-1 induction, the sequence of the EGFR
promoter between nucleotides 31109 and 3911 was analyzed
for potential IRF-1 binding sites (Fig. 3a). By comparing this
sequence with the IRF-1 and the ISRE consensus binding
sequences G(A)AAAG/C/T/CGAAAG/CT/C and A/GNGAAA-
NNGAAACT respectively [21], two oligonucleotides encom-
passing nucleotides 31035 to 3989 (EGFRp-75) and 3976 to
3934 (EGFRp-132) were synthesized and used in EMSAs to
determine if IRF-1 could bind to this region (Fig. 3a). As
shown in Fig. 3b lane 3, IRF-1 was able to bind to 32P-labeled
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Fig. 1. EGFR gene expression is induced by IRF-1. a: Schematic
diagram of pERLUC-1. b: IRF-1 induction of the EGFR promoter.
U3A cells (3^6U105) were transfected with 0, 50, 500, 1000 and
1500 ng of pAct (IRF-1) or control plasmid LK440, in the presence
of 500 ng of pERLUC-1. 24 h post transfection cells were harvested
and luciferase activity was measured. E and 7 represent the induc-
tion of pERLUC-1 by IRF-1 and control vector respectively. c:
IRF-1 induction of endogenous EGFR. Subcon£uent MCF-7 cells
were transfected with 1500 ng of pAct-1 (IRF-1) for 24 h. A total
protein extract was prepared and 30 Wg was loaded onto a 4^12%
SDS-polyacrylamide gel and analysed by Western blotting.
Fig. 2. The 5P end of the EGFR promoter is required for inducibil-
ity by IRF-1. a: Schematic diagram of EGFR reporter constructs.
Full-length and deletion mutants of the EGFR promoter were fused
to the luciferase gene. b: IRF-1 induction of EGFR promoter dele-
tion mutants. MCF-7 cells (3^6U105) were transfected with 500 ng
of each of the EGFR promoter construct, pERLUC-1, pERLUC-4,
pERLUC-5, pERLUC-6 and pERLUC-9, in the presence of 1500
ng of pAct-1 (IRF-1). The empty vector LK440 was used as a con-
trol. Cells were harvested after 24 h and the luciferase activity was
measured.
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IRF-1-3n, an oligonucleotide containing the IRF-1 binding
site. EMSAs using EGFRp-75 and EGFRp-132 indicated
that although these two EGFRp oligonucleotides do not con-
tain the perfect IRF-1 binding site, IRF-1 binds to these se-
quences as well (Fig. 3b, lanes 6 and 9, respectively). The
complexes IRF-1/EGFRp-75 and IRF-1/EGFRp-132 mi-
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Fig. 3. IRF-1 binds speci¢cally to sequences in the EGFR promoter. a: EGFRp-75 and EGFRp-132 oligonucleotide sequences. EGFRp oligo-
nucleotides were derived from the EGFR promoter, nucleotides 31035 to 3989 and nucleotides 3976 to 3934, respectively. b: EMSAs of
IRF-1 binding to EGFRp-75 and EGFRp-132 oligonucleotides. The control for each oligonucleotide was the reticulocyte lysate alone (lanes 2,
5 and 8). c: Competition assays for IRF-1 binding. Unlabeled IRF-1-3n oligonucleotide was used to compete with 32P-labeled EGFRp-75 and
EGFRp-132 oligonucleotides using EMSAs. IRF-1 (2 Wl) was incubated with labeled EGFRp-75 (lane 1) and EGFRp-132 (lane 4) alone or in
combination with a 1:1000 molar ratio of cold IRF-1-3n (lanes 2 and 5). d: Reverse competition analysis. Labeled IRF-1-3n was competed
with cold EGFRp-75 (left panel) and EGFRp-132 (right panel) oligonucleotides at increasing molar ratios up to 1:3000 (lanes 3^6) using EM-
SAs.
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grated to the expected location relative to the IRF-1/IRF-1-3n
complex.
To examine the speci¢city of the IRF-1 binding to the
EGFR promoter, we performed EMSAs with competition.
Cold IRF-1-3n and a non-speci¢c oligonucleotide were used
to compete with 32P-labeled EGFRp-75 and EGFRp-132 oli-
gonucleotides for IRF-1 binding. IRF-1-3n competed with
both EGFRp oligonucleotides (Fig. 3c, lanes 2 and 5) while
the non-speci¢c oligonucleotide (NS) at the same molar ratio
had no e¡ect on the binding (Fig. 3c, lanes 3 and 6). In a
reverse competition assay, EGFR oligonucleotides EGFRp-75
and EGFRp-132 were used as competitors with the 32P-la-
beled IRF-1-3n. As displayed in Fig. 3d, both oligonucleotides
competed with IRF-1-3n in a concentration-dependent man-
ner. To obtain complete competition, a 3000-fold molar excess
of EGFRp-132 (right panel, lane 6) and a 1000-fold molar
excess of EGFRp-75 (left panel, lane 4) were required. The
requirement for this large excess of competitor is unusual but
is consistent with previous reports by Tanaka et al. [22].
Although these data show that IRF-1 can bind to DNA ele-
ments in the EGFR promoter, IRF-1 can also activate gene
transcription through protein-protein interaction with other
transcription factors such as HMGI(Y) and NF-UB [23].
The physical interaction of IRF-1 to these transcription fac-
tors facilitates its DNA binding activity. In addition, it has
been suggested that the IRF family may increase transcription
activity by altering chromatin structure [24]. This could be the
result of direct binding and recruitment of histone acetyltrans-
ferases such as PCAF [25]. Histone acetylation has been
shown to be an important process in controlling gene expres-
sion [26]. Thus, we examined whether IRF-1 induction of
EGFR promoter activity was a¡ected by TSA, a deacetylase
inhibitor. U3A cells were cotransfected with IRF-1 and the
full-length EGFR promoter construct, pERLUC-1, followed
by 1 WM TSA treatment. As illustrated in Fig. 4a, IRF-1 and
TSA cooperate in a synergistic fashion to potentiate the in-
duction of the EGFR promoter activity. This indicates that
acetylation may be involved in the IRF-1 induction of the
EGFR promoter activity. IRF-1 or TSA may induce the acet-
ylation and activation of other factors which interact with
IRF-1 to bind the EGFR promoter. There is also an increase
in the activity of the control with TSA alone (Fig. 4a, lane 3).
This is not surprising since TSA is a general inhibitor of
deacetylases. Next, we analyzed whether the region between
31109 and 3911, which was found to be required for the
IRF-1 induction of the EGFR promoter, was also important
for potentiating the IRF-1 induction by TSA. A comparison
was made with the deletion mutant, pERLUC-4 (Fig. 4b),
which is missing the 31101 to 3911 region (Fig. 2a). U3A
cells were cotransfected with IRF-1 and pERLUC-1 or with
pERLUC-4 followed by TSA treatment. Luciferase analysis
showed that although TSA increased the overall activity in the
case of pERLUC-4, it could not potentiate the IRF-1 induc-
tion of the EGFR promoter to the same levels obtained with
pERLUC-1 (Fig. 4b).
These results suggest that IRF-1 may mediate the IFN in-
duction of EGFR expression since IRF-1 is a major transcrip-
tion factor that is induced by IFNs. On the other hand, the
induction of EGFR expression by IRF-1 may be independent
of IFN. IRF-1 can be induced by other factors such as TNF-
K, IL-1, IL-6, ILF, and prolactin [14,27^30]. Until now it was
not clear whether there are factors that have large modulating
activities on this gene. The signi¢cance of this report is two-
fold. First, we propose a pathway for the upregulation of
EGFR by IFN that is mediated by IRF-1. Secondly, we iden-
ti¢ed IRF-1 as a major regulator of the EGFR promoter
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Fig. 4. TSA acts synergistically with IRF-1 to increase the EGFR
promoter activity. U3A cells were cotransfected with 1500 ng IRF-1
or empty vector (LK440) and (a) 500 ng full-length EGFR pro-
moter reported construct, pERLUC-1, or (b) 500 ng deletion mu-
tant pERLUC-4. TSA was added at 1 WM 5 h after transfection.
Luciferase activity was measured 24 h after transfection.
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which can potentially be targeted for therapeutic intervention
to control EGFR expression.
Acknowledgements: We are grateful to Drs. I. Pastan, G. Merlino, M.
Bustin and S-Y. Cheng for critical reading of the manuscript and
helpful discussions. We thank Drs. T. Taniguchi, G. Stark, and K.
Ozato for plasmids and cell lines.
References
[1] LeMaistre, C.F., Meneghetti, C., Howes, L. and Osborne, C.K.
(1994) Breast Cancer Res. Treat. 32, 97^103.
[2] Nicholson, R.I., McClelland, R.A., Gee, J.M., Manning, D.L.,
Cannon, P., Robertson, J.F., Ellis, I.O. and Blamey, R.W. (1994)
Breast Cancer Res. Treat. 29, 117^125.
[3] Budillon, A., Tagliaferri, P., Caraglia, M., Torrisi, M.R., Nor-
manno, N., Iacobelli, S., Palmieri, G., Stoppelli, M.P., Frati, L.
and Bianco, A.R. (1991) Cancer Res. 51, 1294^1299.
[4] Iacopino, F., Ferrandina, G., Scambia, G., Benedetti-Panici, P.,
Mancuso, S. and Sica, G. (1996) Anticancer Res. 16, 1919^1924.
[5] Johnson, A.C., Ishii, S., Jinno, Y., Pastan, I. and Merlino, G.T.
(1988) J. Biol. Chem. 263, 5693^5699.
[6] Johnson, A.C. (1996) J. Biol. Chem. 271, 3033^3038.
[7] Ludes-Meyers, J.H., Subler, M.A., Shivakumar, C.V., Munoz,
R.M., Jiang, P., Bigger, J.E., Brown, D.R., Deb, S.P. and Deb,
S. (1996) Mol. Cell. Biol. 16, 6009^6019.
[8] Englert, C., Hou, X., Maheswaran, S., Bennett, P., Ngwu, C.,
Re, G.G., Garvin, A.J., Rosner, M.R. and Haber, D.A. (1995)
EMBO J. 14, 4662^4675.
[9] Kageyama, R., Merlino, G.T. and Pastan, I. (1988) J. Biol.
Chem. 263, 6329^6336.
[10] Hudson, L.G., Santon, J.B. and Gill, G.N. (1989) Mol. Endocri-
nol. 3, 400^408.
[11] Caraglia, M., Leardi, A., Corradino, S., Ciardiello, F., Budillon,
A., Guarrasi, R., Bianco, A.R. and Tagliaferri, P. (1995) Int.
J. Cancer 61, 342^347.
[12] Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama,
M., Furia, A., Miyata, T. and Taniguchi, T. (1989) Cell 58, 729^
739.
[13] Harada, H., Takahashi, E., Itoh, S., Harada, K., Hori, T.A. and
Taniguchi, T. (1994) Mol. Cell. Biol. 14, 1500^1509.
[14] Reis, L.F., Harada, H., Wolchok, J.D., Taniguchi, T. and Vilcek,
J. (1992) EMBO J. 11, 185^193.
[15] Coccia, E.M., Marziali, G., Stellacci, E., Perrotti, E., Ilari, R.,
Orsatti, R. and Battistini, A. (1995) Virology 211, 113^122.
[16] Muller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T.,
Darnell Jr., J.E., Stark, G.R. and Kerr, I.M. (1993) EMBO J. 12,
4221^4228.
[17] Vickers, P.J., Dickson, R.B., Shoemaker, R. and Cowan, K.H.
(1988) Mol. Endocrinol. 2, 886^892.
[18] Davidson, N.E., Gelmann, E.P., Lippman, M.E. and Dickson,
R.B. (1987) Mol. Endocrinol. 1, 2^223.
[19] Chang, E.H., Ridge, J., Black, R., Zou, Z.Q., Masnyk, T., No-
guchi, P. and Harford, J.B. (1987) Proc. Soc. Exp. Biol. Med.
186, 319^326.
[20] Chakravarthy, A., Pollak, M. and Hamburger, A.W. (1991)
J. Interferon Res. 11, 1^8.
[21] Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Ki-
mura, T., Kitagawa, M., Yokochi, T., Tan, R.S., Takasugi, T.,
Kadokawa, Y., Schindler, C., Schreiber, R.D., Noguchi, S. and
Taniguchi, T. (1996) Genes Cells 1, 995^1005.
[22] Tanaka, N., Kawakami, T. and Taniguchi, T. (1993) Mol. Cell.
Biol. 13, 4531^4538.
[23] Neish, A.S., Read, M.A., Thanos, D., Pine, R., Maniatis, T. and
Collins, T. (1995) Mol. Cell. Biol. 15, 2558^2569.
[24] Rubinstein, R.Y. (1997) in: IFN-alpha and IFN-tau Induction of
p21 (cdK Inhibitor) and Other IFN Inducible Genes in U937
Cells Over-expressing the IRF-2 DBD, pp. 121^133, University
of Maryland, College Park, MD.
[25] Masumi, A., Wang, I., Kuwata, T., Yang, X., Nakatani, Y. and
Ozato, K. (1997) J. Interferon Cytokine Res. 17, S49.
[26] Wade, P.A., Pruss, D. and Wol¡e, A.P. (1997) Trends Biochem.
Sci. 22, 128^132.
[27] Watanabe, N., Sakakibara, J., Hovanessian, A.G., Taniguchi, T.
and Fujita, T. (1991) Nucleic Acids Res. 19, 4421^4428.
[28] Abdollahi, A., Lord, K.A., Ho¡man-Liebermann, B. and Lieber-
mann, D.A. (1991) Cell Growth Di¡er. 2, 401^407.
[29] Fujita, T., Reis, L.F., Watanabe, N., Kimura, Y., Taniguchi, T.
and Vilcek, J. (1989) Proc. Natl. Acad. Sci. USA 86, 9936^9940.
[30] Yu-Lee, L.Y., Hrachovy, J.A., Stevens, A.M. and Schwarz, L.A.
(1990) Mol. Cell. Biol. 10, 3087^3094.
FEBS 20537 20-7-98
Y.R. Rubinstein et al./FEBS Letters 431 (1998) 268^272272
